The U.S. Food and Drug Administration (FDA) issued a warning letter on July 13, 2026, to a Florida-based dietary supplement manufacturer, citing multiple violations of current good manufacturing practices (CGMP) regulations. The letter detailed significant issues related to sanitation control, quality control, and allergen management, which resulted in the production of adulterated dietary supplements.
According to the FDA's findings, the company failed to establish and follow proper procedures to prevent contamination of its products. Specifically, the inspection revealed inadequate cleaning and maintenance protocols for equipment and facilities, creating an environment where products could become contaminated. The FDA emphasized that such conditions directly violate federal regulations designed to ensure the safety and quality of dietary supplements.
A critical concern highlighted in the warning letter was the company's failure to control allergens. The FDA noted that the manufacturer did not implement sufficient measures to prevent cross-contamination of allergens from one product to another. This lapse poses a significant risk to consumers with allergies, as undeclared allergens can trigger severe or life-threatening reactions. The agency requires supplement manufacturers to have robust systems in place to identify, segregate, and prevent the commingling of allergenic ingredients.
The FDA's letter also pointed to the company's insufficient quality control operations. Manufacturers are required to establish a quality control unit responsible for approving or rejecting all processes, specifications, and procedures that may affect the product's quality. The identified deficiencies indicate a systemic failure to ensure that products consistently meet established specifications for identity, purity, strength, and composition. The company has been directed to respond to the FDA with a detailed plan of corrective actions to address all observed violations and ensure future compliance with CGMP regulations.